CDK 4/6 Inhibitors Boost Overall Survival in Advanced Breast Cancer

Home Blog CDK 4/6 Inhibitors Boost Overall Survival in Advanced Breast Cancer

Maturing clinical trial data indicated that treatment with CDK 4/6 inhibitors offer a survival advantage to women with advanced breast cancer, according to new research. Two different clinical trials, MONARCH 2 trial and MONALEESA-3 trial, studied treatments with abemaciclib (Verzenio) plus fulvestrant and ribociclib-fulvestrant respectively.

Researchers found that the overall survival rate was positive with both clinical trials. Data from both studies has been considered highly meaningful data and a game changer. The research was recently presented at the European Society for Medical Oncology (ESMO) annual meeting.

"I think these results will make a huge impact on how we treat metastatic breast cancer," Nadia Harbeck, MD, PhD, of the University of Munich stated, adding that most European registries indicate OS of about 2 years in metastatic breast cancer, but results from MONARCH AND MONALEESA-3 indicate that extended survival is possible.

Read the full story from Medpage Today.

0 comments

Back to Top